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 ABSTRACT 
 
OBJECTIVE: The objective of this systematic review is to determine whether or not stimulant-
type medications help to improve cognitive function and apathy in geriatric patients. 
 
STUDY DESIGN: Systematic review of three English language primary studies published in 
2001 and 2008. 
 
DATA SOURCES: Two randomized control trials and one individual randomized control trial 
comparing methylphenidate administration to placebo for improvement in cognitive function and 
apathetic mood in elderly patients were obtained using PubMed.  
 
OUTCOMES MEASURED: Clinical outcomes of apathy were measured according to the 
Apathy Evaluation Scale (AES), Neuropsychiatric Inventory (NPI), the Montgomery Asberg 
Depression Rating Scale (MADRS) and the Barthel Index both before and after the 
administration of methylphenidate or placebo. One study measured improvements in cognitive 
function after the administration of methylphenidate. Cognitive function was measured through a 
computerized neuropsychological test known as Go-NoGo.  
 
RESULTS: In the study by Ben-Itzhak et al, cognitive function scores were significantly 
improved from baseline after the administration of methylphenidate (P = 0.03), whereas there 
was no improvement from baseline after administration of a placebo (P = 0.96). Herrmann and 
colleagues showed a statistically significant (P = 0.047) improvement in AES scores (a decline in 
apathetic symptoms) after the administration of methylphenidate compared to the placebo. 
Unfortunately, multiple participants experienced adverse effects of the medication, which 
resolved upon discontinuation (NNH =7). In the study by Jansen et al, clinically significant 
treatment effect was shown in two depressed individuals with improvement in their MADRS 
score and one patient with improvement in their AES score. One patient could not complete the 
study.  
 
CONCLUSIONS: Improvement in cognitive function and apathy were demonstrated by the 
administration of methylphenidate in all three studies. The results of the randomized control trial 
by Ben-Itzhak et al demonstrate overall improvement in executive function, specifically, higher 
cognitive processes, after the administration of methylphenidate. Herrmann and colleagues were 
able to prove that stimulants improve features of apathy, but adverse effects must be considered. 
Jansen et al concluded that single-patient trials are effective in determining the overall 
significance of methylphenidate use for apathy in depressed geriatric patients.  
 
KEY WORDS: methylphenidate, apathy, elderly, cognitive function, aging.  
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INTRODUCTION 
 
 Apathy, defined as a lack of motivation, is recognized as a psychiatric syndrome common 
among the elderly1. Apathetic states are associated with a decrease in executive function, 
specifically cognitive function and an overall decrease in daily function1. This paper evaluates 
two double blind, cross-over, randomized control trials (RCT) and one individual, cross-over 
RCT comparing the efficacy of methylphenidate as an oral medication for improving cognitive 
function and apathy in geriatric patients.  
 Apathy is frequently seen among geriatric patients solely as a psychiatric syndrome or it 
may be seen as a symptom in other diseases, specifically in dementia, Parkinson’s disease or 
depression2.  It is important to distinguish apathy from depression. Although each share common 
symptoms, those unique to apathetic patients include: blunted emotional response, indifference, 
low social engagement, diminished initiation and poor persistence1. Physiologically, it is known 
that apathy is a result of dysfunction in the frontal-subcortical circuits. This is significant in the 
scope of practice because the frontal-subcortical circuits aid in motivated behavior, the 
organization of information and the integration of limbic and emotional information3. Bonelli & 
Cummings described these circuits as effector mechanisms that allow a person to “act on their 
environment”3. There is a strong link between frontal-subcortical dysfunction and 
neurodegenerative disorders. In fact, apathy is present in seventy percent of patients diagnosed 
with Alzheimer’s disease4.   
 Apathy can affect an individual’s cognitive function. It is important to note the 
relationship between apathy and decreased cognitive functions in elderly patients because 
cognitive processes help regulate behavior and attention. As behavior and attention are altered, 
an individual will have a decrease in their overall executive function5. This decline in executive  
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function alters mobility and gait leaving elderly patients susceptible to falls and medical 
injuries5. In 2003, 1.8 million elderly patients were treated in the emergency room for fall 
injuries correlating with decreased executive and cognitive function5.  
 An exact number for the total healthcare cost for apathy and decreased cognitive function 
among elderly patients has not been identified. However, in 2003 the national health expenditure 
for mental health services was estimated to be over $100 million6. There is not an exact estimate 
available for the number of healthcare visits each year associated with apathy. Yet, it is 
important to note the correlation between apathy and those with decreased cognitive function 
because a significant number of those patients are diagnosed with degenerative dementia with 
Alzheimer’s being the most common type2.  
 Due to the strong correlation between neurodegenerative disorders, decreased cognitive 
function and apathy, the treatment options overlap. The pharmacological options are specifically 
formulated to treat the symptoms or progression of neurodegenerative disorders with 
improvement in apathy and cognitive function as an added bonus. Specifically, cholinesterase 
inhibitors (ChEi) showed improvement in apathy scores among patients diagnosed with 
dementia1. Dopaminergic agents showed improvement in apathy scores among those diagnosed 
with Parkinson’s disease1. Non-pharmacological treatment alternatives for apathy include 
behavior, music and art therapy1.  
 The use of methylphenidate, a CNS stimulant medication, is being proposed for 
improving both apathy and cognitive function in geriatric patients. Currently, there is no 
definitive treatment for elderly patients suffering from apathy and diminished cognitive function. 
The pharmacological and nonpharmacological treatments listed above show slight improvement 
in only some patients. Therefore, it is important to further study methylphenidate as an oral
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alternative to improve cognitive function and diminish apathy-like symptoms among the geriatric 
population.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not stimulant-type 
medications help improve cognitive function and apathy in geriatric patients.   
METHODS 
 Specific criteria were set forth to ascertain proper selection of similar studies. The criteria 
used for the selection of the three studies included elderly patients with evidence of apathy, 
decreased cognitive function or both. Intervention included the administration of 
methylphenidate. The dosing and strength of medication varied among the three studies and 
included 5 mg, 10 mg or 20 mg tablets given orally once or twice per day. Each of the three 
studies compared the treatment group, receiving methylphenidate, to the experimental group, 
receiving a placebo. One double-blind, placebo controlled, cross-over RCT and one double-
blind, individual, cross-over RCT measured the efficacy and tolerability of methylphenidate for 
the treatment of apathy in elderly patients. The other double-blind, placebo controlled, cross-over 
RCT measured the efficacy and tolerability of methylphenidate for the improvement of cognitive 
function in community-living elderly adults.  
 Data sources for the systematic review were selected from PubMed. Key words used to 
search for the articles included “methylphenidate”, “apathy”, “elderly”, “cognitive function” and 
“aging”. All articles were published in peer-reviewed journals and printed in English. All articles 
were selected based on their relevance to the clinical question and their inclusion of selected 
patient-oriented evidence that matters (POEMS). Inclusion criteria included subjects who were 
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older than 55 years of age; additional criteria were defined by specific studies (Table 1). 
Exclusion criteria included certain medical conditions that would be negatively affected by 
the administration of a stimulant-type medication, most notably patients with heart disease 
(Table 1). Statistics reported and used to evaluate patient’s outcomes included p-values, Z scores 
and numbers needed to harm (NNH). The demographics and characteristics of the studies are 
shown in Table 1.  
Table 1: Demographics and Characteristics of Included Studies 
Study Type # of 
pt’s 
Age 
(yr) 
Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Ben-
Itzhak5 
(2008) 
Double-
blind, 
placebo 
controlled, 
cross-over, 
RCT 
26 65-90 Only subjects who complained 
about memory decline were 
included; Could ambulate 
independently; no use walking aid  
 
Dementia, MMSE 
score <24, 
Clinically sig 
MSS, cardio, resp 
dz or vestibular 
d/o, Hx of sig. 
head trauma, PD 
or other neuro 
deg. d/o, 
MDD,Uncontroll
ed HTN, hf, 
arrhythmia or hx 
of epilepsy, Rx 
for MAOI’s or 
TCA’s   
 
0 Administration of 
methylphenidate (20 mg) and 
placebo on resulting effects 
on pt’s cognitive function 
Herrmann4 
(2008) 
Double-
blind, 
placebo 
controlled, 
cross-over, 
RCT 
13 >55 Pt’s were recruited from 3 different 
dementia clinics, age > 55, mild to 
moderate cognitive impairment 
based on MMSE (score > 10), 
presence of apathy based on the NPI 
(score >1), stabilized on a ChEI for 
at least 3 mo and no other 
psychotropic meds 
 
Sig. medical or 
neuro conditions 
which diminish 
cognitive fx, A-
fib,  
uncontrolled 
HTN, evidence of 
a seizure d/o, 
psychiatric dx, 
current use of any 
psychotropic 
medications other 
than a ChEI, 
psychotic sx or 
cardiac probs 
 
2 The administration of 
methylphenidate for the 
treatment of apathy in elderly 
patients with Alzheimer’s 
disease 
(5 mg PO BID. 3 days, then 
10 mg PO BID x 11 days) 
Jansen2 
(2001) 
Individual 
cross-over, 
double-
blind, RCT 
5 76-81 Geriatric, depression due to a 
general medical condition, 
resistance to antidepressant med & 
chronic apathy due to dementia 
None b/c of the 
study design   
1 methylphenidate for the 
treatment of depression or 
apathy in geriatric patients (5 
mg BID and placebo) 
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OUTCOMES MEASURED 
 All outcomes measured were POEMS related to improvement in apathy scores and 
cognitive function scores. Ben-Itzhak et al examined the effect of a single dose of 
methylphenidate on cognitive function. A computerized neuropsychological test, known as Go-
NoGo, was used to measure cognitive function. Go-NoGo is a test of executive function that 
measures a participant’s ability to illicit a response and continue with activity when faced with a 
competing stimuli. Outcomes were reported as p-values, where a p-value less than or equal to 
0.05 deemed significant5. 
 Herrmann and colleagues designated the Apathy Evaluation Scale (AES) as the primary 
outcome variable. The AES score is reported between 0-72, where a higher score denotes worse 
apathy. They compared treatment AES score to the baseline AES score (treatment – baseline) 
and reported values as Wilcoxon Z signed-rank tests, an alternative to the simpler paired t-test4. 
Furthermore, this study also used the Neuropsychiatric Inventory (NPI) scale both as a baseline 
for the presence of apathy and again during the treatment and placebo phases. Negative change 
scores indicate improvement on the AES and NPI4.  
 In addition to measuring outcomes via AES, Jansen et al also measured depression using 
the Montgomery Asberg Depression Rating Scale (MADRS). Scores can range from 0-60, with 
higher scores representing worse depressive symptoms. Clinically significant outcomes were 
defined by statistically significant improvement of AES or MADRS scores that were analyzed 
with a one-sided paired t-test. The Barthel Index was used to report activities of daily living2.  
RESULTS 
This systematic review examined three randomized control trials for the efficacy and 
tolerability of methylphenidate for the improvement of apathy and cognitive function in elderly
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adults. All of the studies used a control group (placebo) and a treatment group (methylphenidate) 
with comparisons made to baseline assessments.  
Ben-Itzhak and colleagues studied 26 elderly adults without a diagnosis of dementia, but 
with self-reported “memory problems”5. A randomized, double blind, crossover, placebo 
controlled trial was performed. Each participant underwent a 2-week study that began with an 
initial baseline assessment including a computerized cognitive test known as Go-NoGo. A single 
dose of methylphenidate 20 mg or a placebo were given to randomly chosen participants with 
measurements taken 2 hours post tablet administration. The time frame of 2 hours was carefully 
chosen as that is when the peak plasma concentration of methylphenidate occurs5. Statistical 
analysis revealed that methylphenidate significantly improved Go-NoGo accuracy when 
compared to the placebo (P = 0.03) and when compared to baseline (P = 0.03). There was no 
improvement in baseline compared to the placebo (P = 0.96) further supporting the initial 
hypothesis (Table 2)5. No adverse events were reported in response to the administration of 
either methylphenidate or placebo. Blood pressure and heart rate were measured in half-hour 
intervals before and after the administration of medication to record possible cardiovascular 
effects due to the administration of a CNS stimulant5.  
Herrmann and colleagues recruited 13 patients from 3 different community clinics. All of 
the participants had a previously established diagnosis of Alzheimer’s disease and showed 
evidence of apathy according to initial NPI apathy scores4. Herrmann et al performed a 5-week 
crossover study where participants received methylphenidate or a dose equivalent placebo for 2 
weeks, followed by a placebo washout phase for 1 week and then a treatment phase for an 
additional 2 weeks. The medications started at 5 mg PO twice a day for 3 days and then 
increased to 10 mg PO twice a day for 11 days. The participants were assessed at the start of the 
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first treatment (week 0), the end of the first treatment (week 2), the start of the second treatment 
(week 3) and the end of the second treatment (week 5). Assessment consisted of total change 
scores from baseline to treatment in both the NPI apathy scale and AES scores. In general, the 
participants showed greater improvement in AES scores with methylphenidate when 
compared to a placebo (Z= -2.31, P = 0.045) (Table 3). There was also a difference in NPI 
apathy scale scores when looking at methylphenidate treatment versus the placebo, but the 
difference was not statistically significant (Z= -1.92, P = 0.76) (Table 3). Herrmann et all 
attribute this to the vast difference between the AES and NPI scale scores to the simple fact that 
the AES scale detects the presence of apathetic symptoms and the NPI scale determines the 
severity and frequency of apathetic symptoms4.  
In a third study, Jansen et al recruited 5 geriatric patients to participant in an individual 
randomized control trial, also known as “N of 1” trials. All 5 of the participants were previously 
diagnosed with depression or apathy. The patients participated in a 5-week study where each 
week contained 2 double-blind drug periods (methylphenidate 5 mg twice a day or placebo) each 
lasting 2 days (Monday/Tuesday and Thursday/Friday)2. Assessments of MADRS and AES 
scores were done at the end of each period, which occurred on Tuesday and Friday afternoons. 
Statistically significant results were defined by improvement on the MADRS, AES or Barthel 
Index. The results demonstrated a significant improvement in the MADRS score of 2 participants 
(P =0.089, P = 0.001) as well as significant improvement in the AES score of an apathetic patient    
(P = 0.077) (Table 4). One participant showed no improvement in their depressive symptoms. 
None of the participants showed significant changes in functional performance as measured by 
the Barthel Index. One participant dropped out of the study after the first week due to the 
development of unrelated mutism2.
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SAFETY  
Unfortunately for Herrmann and colleagues, 3 of 13 participants experienced adverse 
effects when methylphenidate was administered. The adverse effects ranged from mild to severe, 
where dry mouth was classified as a mild event. The more severe events included, but are not 
limited to flushing of the face, anger, delirium, insomnia, nightmares, decreased appetite and 
physical aggression. The intensity of the adverse effects was severe enough to cause 2 of the 13 
participants to drop out of the study. The third participant completed the study despite the mild 
effects of methylphenidate. The overall number needed to harm (NNH) was 7, which is large 
given the relatively small population size (Table 5). A NNH of 7 is significant because for every 
7 individuals treated with methylphenidate, one of those will experience adverse effects that they 
would not have otherwise experienced without the drug. 
 
Table 2: A comparison of the effects of methylphenidate and placebo on cognitive function5  
Measurement of 
Cognitive Function 
Baseline vs Placebo Baseline vs 
Methylphenidate 
Methylphenidate 
vs Placebo 
Go-NoGo accuracy .96 .03 .03 
 
 
Table 3: Treatment change scores (end of treatment compared to baseline) comparing the effect 
of methylphenidate and placebo phases on apathy symptoms4  
 Methylphenidate Placebo 
 
P (Wilcoxon Z) 
AES  -2.31 (5.11) 0.50 (3.87) 0.045 
NPI  -1.92 (7.56) -2.08 (12.24) 0.76 
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Table 4: Individual changes in apathy or depression from baseline after the administration of 
methylphenidate2 
Participant 
Number 
Assessment 
Instrument 
Mean Change (SD) P-Value 
1 MADRS -1.6 (2.2) 0.089* 
Barthel -0.2 (0.4) 0.187 
2 MADRS -4.0 (1.2) 0.001* 
Barthel 0.2 (0.4) 0.187 
3 MADRS 3.4 (0.5) 0.089 
Barthel -0.4 (7.9) 0.196 
4 AES (clinican) -2.8 (3.6) 0.077* 
AES (informant) -6.2 (8.3) 0.086* 
Barthel 0.2 (0.8) 0.310 
*Clinically significant 
 
Table 5: Analysis of adverse events from methylphenidate administration using dichotomous 
data4 
CER EER RRI ARI NNH 
0.077 0.23 1.98 .153 6.53 à 7 
 
 
DISCUSSION  
 This systematic review examined three RCTs for the efficacy and tolerability of 
methylphenidate for the improvement of apathy and cognitive function in elderly adults. 
Although proved to be an effective treatment by researchers, many practitioners may hesitate to 
initiate methylphenidate in geriatric patients due to its adverse reactions, most notably those that 
are psychiatric or cardiac related. Methylphenidate is a CNS stimulant FDA approved to control 
the symptoms of attention deficit disorder (ADD), attention deficit hyperactivity disorder 
(ADHD) and narcolepsy, a sleeping disorder7. It works by increasing excitatory 
neurotransmitters in the brain, specifically dopamine and norepinephrine, precipitating addiction 
potential7. Common side effects of the medication include nervousness, weight loss, trouble 
sleeping, insomnia, nausea and headache. Methylphenidate should be used with caution in 
patients who have high blood pressure, glaucoma, heart problems and mental or mood conditions 
as the medication could exacerbate underlying disease7.
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  Methylphenidate is readily available in the United States. The drug comes in different 
variations including immediate release tablets and extended release capsules. The medication is 
routinely prescribed to children who are diagnosed with ADD or ADHD. In recent years, 
prescription insurance plans have declined to pay for CNS stimulant mediations after the age of 
30 and a complicated prior authorization process must be initiated before the patient can receive 
their medication. Therefore, methylphenidate use in elderly patients will come as a hassle to 
prescribers who need to fill out extra paperwork.   
CONCLUSION  
Each of the three studies proved the administration of methylphenidate to be beneficial 
for geriatric patients suffering from apathy or decreased cognitive function. Although the three 
RCTs demonstrated improvement in apathy and cognitive function, the studies do not come 
without limitation. All 3 of the research teams recruited extremely small sample sizes. Research 
in this field needs to encompass larger population sizes due to the relatively high NNH compared 
to the small sample size, as demonstrated by Herrmann et al.  
Future study to evaluate the effects of methylphenidate on elderly adults is warranted 
before consistent use is recommended. Fortunately, ongoing clinical trials and research studies 
are in motion. In fact, John Hopkins Bloomberg School of Public Health is doing just so. 
Hopkins clinical trial, The Apathy in Dementia Methylphenidate Trial (ADMET) is a placebo 
controlled, phase 2, clinical trial examining exactly what was enclosed in this systematic review: 
the efficacy and safety of methylphenidate for those already diagnosed with dementia8. It is 
important for researchers to examine the full extent of the benefits, safety and risks of 
medications that are being prescribed for off-label use. 
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